Loading...
Loading...
Morgan Stanley analysts David Lewis and Scott Wang reviewed Johnson & Johnson
JNJ after the US patent office rejected its 2018 patent of Remicade. Morgan Stanley currently rates Johnson & Johnson as Equal Weight.
Johnson & Johnson is expected to appeal to the Patent Approval Board in the coming months however if unsuccessful there is potential for an earlier than anticipated US biosimilar Remicade competition among smaller biotech companies who are developing their own version of the drug. Celltrion Inc. and Epirus Biopharmaceuticals
EPRS are currently far along with the FDA and hope to get continue the approval process of their drug.
Regarding the risks for Johnson & Johnson, the analysts wrote, "The risk for J&J is twofold: biosimilar approval creates potential for share losses; and will likely lead to significant pricing pressure, as evidenced by market commentary post the recent expiry of Remicade patents in Western Europe."
Johnson & Johnson has traded at $98.52.
Epirus Biopharmaceuticals has traded at $6.79.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in